{"entity":{"id":"ibi3014","kind":"drug","name":"IBI3014","aka":[],"tldr":"IBI3014 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.","summary":"AACR 2025 abstract 344 describes a TROP2/PD-L1 bispecific ADC with an NT1 TOP1 inhibitor payload. The abstract reports cell and xenograft activity, stability and monkey toxicology, not clinical efficacy. NCT06974812 separately registers a recruiting phase 1/2 study. A clinical registry entry does not convert the preclinical comparisons into evidence of patient benefit or a validated safety advantage.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"Publisher abstract","url":"https://doi.org/10.1158/1538-7445.am2025-344"},{"label":"ClinicalTrials.gov NCT06974812","url":"https://clinicaltrials.gov/study/NCT06974812"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc","bispecific-adc"],"targets":["trop2","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06974812"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"ADC","payload":"NT1 (TOP1 inhibitor)","mechanism":"Bispecific TROP2/PD-L1 antibody-drug conjugate combining NT1 delivery with immune checkpoint blockade.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ibi3014/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct06974812","kind":"trial","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06974812/"}]}}